ology for chemical synthesis and testing of libraries of milJions of chemical entities has been for rapid molecular and cellular screening for drug leads. Each individual compound in the on a separate resin bead. Screening for binding activity can be conducted directly on the logical activity is assessed in solution phase assay by cleaving a portion of the compound bead. The molecular structure of the compound of interest is obtained by automated peptide g from the bead of origin. We have applied this technology to anticancer drug discovery as other pharmaceutical targets. For anticancer drug development, current molecular targets cell lymphoma, the EGF receptor, and rhe HER2-neu receptor. Solntion phase screening with able libraries is being used for growth inhibition of human tumor cell lines. Initial in vitro been identified in each of these areas of anticancer drug discovery.
r drug discovery has focused on two major : rational drug design and random screening of synthetic products. Both approaches have e success, and there are now over 40 anticancer nical use. The majority of current anticancer atural products or their semi-synthetic derivaant alkaloids or natural products. When apirh random screening, 50000-100000 unique evaluated in order to discover a promising Despite progress to date. there is major separately on an individual bead. binding fluorescent or enzyme marker-coupled me,)",u),,, were used to identify unique peptides that antibody, enzyme or receptor. The technique quite effective for high volume testing as library containing millions of compounds sized within a few days. Screening of a library peptides using one of the marker-bead u"'uw,. as! be accomplished within a single day.
Using several model macromolecular established that structurally unique high from within a series of penrapeptide approximately three million different could readily be identified (1). For epitope cific staining of the few beads within a specifically to a tagged monoclonal rapid means for identifying: 'rrumotopes' immunizing epitope within affinity peptide ligands for an clonal antibody (clone E-7) and for the bie'lin-bhf& of streptavidin were the demonstrations used the specificity of this screening process and it was based on molecular-recognition ( development of this technology for drug quired application of suitable Chemistries, assay techniques.
We have also extended the Selectide l~':~;l;'t esting of free peptides in solution by ir cleavable linkers, with orthogonal cleavage (diketopiperazinc and ester bonds), as non-cleavable linker onto each bead. The synthesized on each of these linkers on an producing a construct where one-third of the be released and tested. subsequently the released and tested. and the final third enabling its identity to be determined provided a means to test massive libraries comprised of either natural or unnatural conventional microplate pharmacological signaling, etc. A two-stage assay wNa~;S~r~:::':~~;,TI volume screening in solution phase IT phase, 500-1 000 beads were placed in each microplate and and the first linker cleaved at fonn a diketopiperazine and release the peptide solution from each well of each then transferred by filtration into a C;:~~~':i;:~:li1f for solution phase testing. After il welI(s)' in the first stage assay, the beads sponding master weI1(s) were then tributed by pipetting into new master plates bead per well (range 0-6) and the second ester bond) was cleaved using either base ammonia to release free peptide. Following filtration and assay, the active well(s) were and the corresponding beads from the second to chemically synthesize small peptide libraries using a multi-pin technique in 96 well plates for epitope mapping. Very large peptide libraries can be generated by inserting a randomized oligonucleotide into the genome of the filamentous phage pilI coat protein (4-6). Such phage libraries can be screened by immune adherence techniques, selecting those phages which express peptides within the pIlI coat protein with the desired ligand binding activity. The adherem phages are then subjected to a series of cloning and expansion steps after which the active peptide is identified by sequencing the phage nucleic acid and determining the peptide sequence from the genetic code. Houghten and his colleagues developed a modification of Geysen's chemical process in which larger batches of peptides of known structure are synthesized and cleaved into solution and screening to identify peptides with various functional activities (7) . As with Geysen's technique. Houghton's approach is also iterative and starts with very short peptides and converges on a lead peptide as additional batches of peptides are produced of longer chain length which incorporate the sequence found in the initial shorter peptide. The Selectide technology utilizes a 'split synthesis' approach for random generation of compounds produced via solid phase chemical synthesis (8) conducted in such a fashion that each individual compound in the library is represented on a separate solid phase resin bead on which it was synthesized (I). The individual beads within the batch of resin beads used for synthesis were divided up into different reaction vessels, one for each reactant species (e.g., amino acid) to be added to a growing polymer or compound. After each cycle of deprotection and building block addition (e.g., using Boc or Fmoc protected amino acids and sufficient time to allow the reaction step to go to completion), the beads were recovered and pooled from the various vessels. washed and thoroughly mixed and then redistributed into the vessels again for the next addition step. In an initial model experiment using three different amino acids to produce a library of tripeptides, all 27 theoretically generated tripeptides were successfully produced and identified and found to be produced in approximately equimolar quantities. Of importance. each individual bead contained a sufficient quantity of its unique peptide to permit its sequence to be determined via Edman degradation using an automated protein sequencer. This approach proved to be readily adaptable to the generation of libraries of various sized peptides (e.g., pentapeptides to dodecapeptides), using as many as 40 amino acids. However, with greter than 'z-mers,complete libraries cannot be synthesized due to size and expense. Therefore, only a percentage of the total structures are synthesized for such libraries.
Using natural or unnatural amino acids and varying peptide length, and by introducing conformational constraints to induce cyclic or alpha-helical structures, a wide variety of library formats was developed. In as much as each individual peptide in the library was represented recovered and subjected to peptide sequencing. ate the specificityof this release-technology for fie ligands. we utilized two molecular targets: i-beta endorphin monoclonal antibody as used ie specificity of the bead binding assay, and the t Ilb/IIIa receptor for fibrinogen (10) . Using gy, we were in fact able to rapidly identify rids for both of these molecular targets. The nology is now being used to evaluate growth ects or other signaling assays that can directly cdonal as well as structural interactions. ies established that we could identify peptides d to the active sites of antibodies and of cell tors. More recently, the technology has been pplied by the Selectide Corporation to identify e inhibitors. We also sought to advance the nology beyond peptldes to the more general organic compounds, as peptides have only been used as drugs. This is because most not retain biological activity after oral adminor do they gain access to the intracellular to The cyclic peptide antibiotic cyelosporine is as it is orally active and also internalized in its the cyclophyllin receptor. The technology for Ibraries of non-peptides (including both polyures based on subunits linked as amides, ureas erivarives of biologically interesting molecular as steroids, sugars. etc.) has proven feasible. if.been built with Selecride process by using a ursor organic molecules that are available in for chemical coupling. Screening of nonrles can be conducted with either the beadase assay screening technologies as described hich the active bead(s) can be recovered. A that had to be addressed with the non-pepwas that of structure determination from the uantities present on a single bead. Some strucdetermined with mass spectroscopy that is not le. Therefore, an encoding technique was sing a peptide to code for each non-sequencere (10). This was accomplished by incorporating id to code for each randomized component of enceable compound. Beads in the non-peptide efore contain two separate structures: a non-se-Iigomer or other organic compound. and a nceable peptide {the amino acids which servẽ •. . • for the structure of the non-sequenccable (J 1). An analogous technique has recently been ). t applications of the Selectide process to anticancer drug discovery rrently using the Selectide technology in an new anticancer drugs. One of us, (KSL), 129 first developed a new concept for using random peptide libraries in order to discover mimotopes which might be used for 'antigen-directed immunotherapy" (ADl) for Bcell non-Hodgkin's lymphoma (13) . This approach was designed to be patient specific and to identify peptides binding to the cell-surface monoclonal immunoglobulin idiotype ('id') which is unique to each individual patient's B-cell lymphoma (14) . The overall concept of ADI includes recovery of cell surface id, identification of a peptide from within the library which binds specifically to the id (and not other immunoglobulin components). followed by resynthesis of and radioiodination of the patient specific peptide for use in radioirnmunorhempy (13) . Use of a peptide to deliver tumor-specific radiotherapy would have the advantage of using a small molecule with more favorable tissue distribution and clearance than a monoclonal antibody for tumor imaging. dosimetry and treatment.
This concept is currently being tested in preclinical models by Dr. Lam at the Arizona Cancer Center. In addition to the logistic obstacles to be overcome in the development of individualized ADI, there is the potential biological obstacle of in vivo evolution of tumor clones expressing variants of the idiotype or no immunoglobulin whatsoever (15) .
In 1992 we substantially expanded efforts at drug discovery using the Selectide technology with a collaborative program involving laboratories at The University of Arizona, New York University, The Max. Plank Institute, The Selectide Corporation and the National Cancer Institute (NCI). This program is intended to discover new anticancer drugs of more general use than described above for B-cell lymphomas. This initiative is supported in part with 'National Cancer Drug Discovery Group', (NCDDG), funding from the NCL In this research. we use both bead binding technology (for specific recombinant receptors) and the release assay technology for identifying antiproliferative peptides. While this is still a new program. we have already obtained preliminary evidence that the Selectide technology can be used for lead discovery for anticancer agents.
Molecular recognition of cancer-related receptors
As one objective in our NCDDG program, we are attempting to identify relatively small peptide ligands which bind to the external domains of tyrosine kinase receptors which are overexpressed in some carcinomas and thought to be involved in the growth signaling process (16) . The specific receptors we are initially studying are the epidermal growth factor receptor (EGFR) and the HER2-Neu oncogene expression product (HER2R), HER2R has structural homology to EGFR, although its specific ligand remains to be confirmed. The recombinant external domains have been expressed in forms that are of particular use for molecular screening efforts. We postulate that a binding peptide that occupies the growth factor binding s. E. SALMON ET AL. approximately one bead per well for The second stage test is performed with the that yielded the positive screening result assay. With a positive second stage the master well is then recovered for automated protein sequencer. The resynthesized and retested against all 6 response fashion. Thus far, we have screening against 10 different library prepared with the dual cleavable linkers, than 30 million individual peptides. At nology development, library format is specific molecular targets have not been the cell line testing. Structural date have included libraries of length (up to lScmers), cyclic structure.
various end-groups added to the amino peptidcs. Complete screening of a library peptide lengths up to 5-mers, but only a chain length libraries can be screened at 3 million individual peptides were tested the libraries tested. To date we have lead antiproliferative peptide with this lipophillic pentnpeptide with differential against the 6 cell lines. The activity profile against the various cell lines was quite of an index antitumor agent (mitomycin-Cj positive control. The greatest degree of with the resynthesized peptide was prostate and colon cell lines. and with the leukemic cell line.
In addition to the work on conventional continuing prospective screening with using new or novel library formats Including conformational constraints. unnatural recently initiated study of releaseable structed of non-amino acid building are constructed to have a non-releaseablc sequence for structure determination.
Discussion
Our studies provide indication that the nology can be applied to anticancer drug have focused on cell surface receptors on our initial molecular targets. However, it enzymes associated with invasion and targets of interest. particularly since this been successfully applied to the Selectide identify inhibitors of proteases. Lead ered from peptide libraries also may serve as subsequent development of P:I,~:j~;:~;;;:~:Iĩ nstances may themselves serve as have great interest in pursuing organic molecules, as 'hits' from these site on either of these receptors may inhibit cancer growth.
For both EGFR and HER2R. the bead binding technology was employed after coupling the extracellular domain of the relevant receptor to either an alkaline phosphatase or a fluorescent tag. With EGFR. the natural ligand EGF can be used in competitive binding studies. This approach increases the specificity of the screening assays and prevides experimental evidence that the discovered peptides bind at the ligand binding site. While a variety of libraries have been screened. our initial leads were obtained from a library of cyclic j-mers. OUf lead peptides bind to EGFR and can block the binding ofEGF. We are not yet certain of the affinity of these peptides for EGFR and they have yet to be tested in functional assays. Additional screening as well as lead optimization based on the initial peptide leads is now underway.
Screening for binding ligands for HER2R is more difficult, as the natural ligand for this receptor-like molecule has not been clearly identified. and has not been available for these studies. Therefore, we cannot carry our competitive binding studies as one of the tests of specificity. The peptide ligands which we determine to bind to HER2R may well bind at alternative sites on the receptor than at the ligand binding site. Functional assays will be required to determine their relevance to HER2R signaling. We have identified some 13-mers which bind with specificity to HER2R. Several Df these appear to inhibit functional tyrosine kinase activity, but their affinity remains indeterminate. Characterization of affinity of these HER2R binding peptides and effect on cell proliferation is in progress.
Cancer cell line screening
The release assay as described above and elsewhere (9) is being utilized in an antiprclifemtive screening program using 6 human tumor cell lines (breast. colon, lung, prostate, melanoma, leukemia) with a replicate plating approach. For first stage screening for antitumor activity the released peptide from each well of the 96 well plates (500-1000 beads per well) is 'divided and simultaneously tested against 2-3 cell lines in a 96-h cell growth inhibition assay. Based on bead content and peptide release characteristics as well as plating volumes of releasate. the maximal test concentration of each peptide is approximately 111M. Drug effect is determined after four days of culture with the sulforhodamine S (SRB) assay with quantitation by spectrophotometry (17) . With releasate from 500 beads per well, each 96 well test plate can be used for the simultaneous evaluation of 50000-100000 pcptides. A single technician can readily plate 20 per day with each cell line, permitting the screening of 1-2 million peptides in each 4-day assay. After a positive well is identified in the first stage assay, the beads from the master plate for that well are recovered and redistributed by pipetting with Cl-IE.\llCAL LlflRARIES FOR ANTICANCER DRUG DISCOVERY irnize than peptides to produce useful drugs, son to hypothesize that compounds within peptide libraries will have a greater probabiling cell membranes and acting on intracellular
